Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12559522 | 0.90 | NOTUM (0.64) | NOTUMALDH1A1TP53MAPTKMT2A | |
| SCHEMBL423295 | 0.86 | NOTUM (1.00) | NOTUMSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL26691238 | 0.85 | NOTUM (0.55) | NOTUMSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL8141492 | 0.83 | NOTUM (0.69) | NOTUMSMN1; SMN2ALDH1A1MAPTDRD2 | |
| SCHEMBL13354612 | 0.83 | NOTUM (0.53) | NOTUMSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL25463664 | 0.82 | NOTUM (0.53) | NOTUMSMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL20733337 | 0.82 | XIAP (0.62) | NOTUMSMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL5793078 | 0.81 | NOTUM (1.00) | NOTUMSMN1; SMN2ALDH1A1TP53DRD2 | |
| SCHEMBL1044559 | 0.81 | NOTUM (0.67) | NOTUMSMN1; SMN2ALDH1A1MAPTKMT2A | |
| SCHEMBL399536 | 0.81 | NOTUM (0.67) | NOTUMSMN1; SMN2ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| EP-3705477-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3216787-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2017147159-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-3210609-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| EP-2502911-B1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMA (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| US-7452873-B2 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452873-B2 | Inhibitors of GSK-3 and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-18 | — | — | US | disclosed |
| US-7384937-B2 | Fused heterocyclic compounds and use thereof | BRISTOL-MYERS SQUIBB CO. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1854798-A2 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | Bristol-Myers Squibb Company (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2007085833-A2 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NOTUM 3670/4885SMN1; SMN2 1945/4885ALDH1A1 4544/4885 |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | NOTUM 1072/4885SMN1; SMN2 4661/4885ALDH1A1 2372/4885 |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | NOTUM 3121/4885SMN1; SMN2 4512/4885ALDH1A1 4677/4885 |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | NOTUM 1072/4885SMN1; SMN2 4661/4885ALDH1A1 2372/4885 |
| US-20170240585-A1 | DEUTERATED BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | NR1H4, GPBAR1, SLC10A1 | NOTUM 804/4885SMN1; SMN2 4733/4885ALDH1A1 2765/4885 |
| US-20080071095-A1 | Cystic fibrosis transmembrane conductance | CFTR, ABCB1, ABCC1 | NOTUM 4344/4885SMN1; SMN2 4860/4885ALDH1A1 2651/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | NOTUM 1437/4885SMN1; SMN2 3054/4885ALDH1A1 623/4885 |
| US-20080293650-A1 | Fused Heterocyclic Compounds and Use Thereof | MCL1, FPR1, LTB4R | NOTUM 3585/4885SMN1; SMN2 2998/4885ALDH1A1 603/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | NOTUM 1437/4885SMN1; SMN2 3054/4885ALDH1A1 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.